JP2013531058A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531058A5
JP2013531058A5 JP2013520221A JP2013520221A JP2013531058A5 JP 2013531058 A5 JP2013531058 A5 JP 2013531058A5 JP 2013520221 A JP2013520221 A JP 2013520221A JP 2013520221 A JP2013520221 A JP 2013520221A JP 2013531058 A5 JP2013531058 A5 JP 2013531058A5
Authority
JP
Japan
Prior art keywords
erlotinib
solvent
base
salt
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013520221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531058A (ja
JP5948597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2011/051394 external-priority patent/WO2012028861A1/en
Publication of JP2013531058A publication Critical patent/JP2013531058A/ja
Publication of JP2013531058A5 publication Critical patent/JP2013531058A5/ja
Application granted granted Critical
Publication of JP5948597B2 publication Critical patent/JP5948597B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013520221A 2010-07-23 2011-07-22 純粋なエルロチニブ Expired - Fee Related JP5948597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2112MU2010 2010-07-23
IN2112/MUM/2010 2010-07-23
PCT/GB2011/051394 WO2012028861A1 (en) 2010-07-23 2011-07-22 Pure erlotinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016093409A Division JP6374436B2 (ja) 2010-07-23 2016-05-06 純粋なエルロチニブ

Publications (3)

Publication Number Publication Date
JP2013531058A JP2013531058A (ja) 2013-08-01
JP2013531058A5 true JP2013531058A5 (enExample) 2014-09-11
JP5948597B2 JP5948597B2 (ja) 2016-07-06

Family

ID=44514823

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013520221A Expired - Fee Related JP5948597B2 (ja) 2010-07-23 2011-07-22 純粋なエルロチニブ
JP2016093409A Expired - Fee Related JP6374436B2 (ja) 2010-07-23 2016-05-06 純粋なエルロチニブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016093409A Expired - Fee Related JP6374436B2 (ja) 2010-07-23 2016-05-06 純粋なエルロチニブ

Country Status (8)

Country Link
US (2) US8952022B2 (enExample)
EP (1) EP2595629A1 (enExample)
JP (2) JP5948597B2 (enExample)
CN (1) CN103124557A (enExample)
AU (1) AU2011298167B2 (enExample)
CA (1) CA2806273A1 (enExample)
NZ (2) NZ628796A (enExample)
WO (1) WO2012028861A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2806273A1 (en) 2010-07-23 2012-03-08 Generics (Uk) Limited Pure erlotinib
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014023027A1 (zh) * 2012-08-10 2014-02-13 上海创诺医药集团有限公司 盐酸埃罗替尼多晶型物及其制备方法
WO2014118112A1 (en) * 2013-01-29 2014-08-07 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN104072427B (zh) * 2013-03-29 2019-05-28 江苏豪森药业集团有限公司 盐酸厄洛替尼晶型的制备方法
WO2020165672A1 (en) 2019-02-15 2020-08-20 Shivalik Rasayan Limited Process for preparation of highly pure fingolimod hydrochloride

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US7625911B2 (en) 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
WO2007060691A2 (en) * 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
ES2573931T3 (es) 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
JP5524041B2 (ja) * 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
US20090012295A1 (en) 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
WO2009007984A2 (en) * 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
EP2218713A1 (en) * 2007-08-17 2010-08-18 Hetero Drugs Limited Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
TW200925152A (en) * 2007-08-23 2009-06-16 Plus Chemicals S A Processes for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCL
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
WO2010040212A1 (en) 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
CA2806273A1 (en) * 2010-07-23 2012-03-08 Generics (Uk) Limited Pure erlotinib

Similar Documents

Publication Publication Date Title
JP2013531058A5 (enExample)
JP2016535081A5 (enExample)
JP2012519207A5 (enExample)
AR083213A1 (es) Proceso de preparacion de derivados pirimidinicos, compuestos intermediarios y proceso para prepararlos
EA201201179A1 (ru) Способ получения изоксазолиновых производных
EP4023641A3 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
MY167395A (en) Method for producing glufosinate p free acid
JP2017501141A5 (enExample)
CN102827153B (zh) 阿齐沙坦的晶型及其制备方法
JP2014511367A5 (enExample)
NZ602450A (en) Agomelatine hydrochloride hydrate and preparation thereof
JP2014507414A5 (enExample)
AR117002A2 (es) Proceso para la preparación de inhibidores de quinasa c-fms
RU2016123144A (ru) Сложноэфирное хиральное соединение (n-замещенный имидазол)-карбоновой кислоты, содержащее простую эфирную боковую цепь, его получение и применение
JP2016517886A5 (enExample)
RU2015151359A (ru) Синтез 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2, 6-диона
JP2014522385A5 (enExample)
RU2018130327A (ru) Улучшенный способ получения осимертиниба (azd9291) или его соли и "анилин-azd9291" или его соли
NZ606042A (en) Process for the preparation of erlotinib and salts thereof
RU2019106531A (ru) Кристалл соли производного хиназолина
JP2015523337A5 (enExample)
JP2022060192A5 (enExample)
RU2016134404A (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА α МОНОБЕНЗОАТА СОЕДИНЕНИЯ А, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЕ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US9745264B2 (en) Method for preparing silodosin and intermediate thereof
RU2012142223A (ru) Пространственно-затрудненные амины